Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NSI 189

Drug Profile

NSI 189

Alternative Names: NSI-189; NSI-189 - Neuralstem; NSI-189 phosphate

Latest Information Update: 28 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuralstem
  • Developer Palisade Bio; University of California, San Diego
  • Class Antidepressants; Antihyperglycaemics; Neuroprotectants; Nootropics; Piperazines; Pyridines; Small molecules; Vascular disorder therapies
  • Mechanism of Action Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angelman syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Preclinical Stroke
  • No development reported Alzheimer's disease; Angelman syndrome; Brain injuries; Cognition disorders; Diabetic neuropathies; Neurodegenerative disorders; Post-traumatic stress disorders; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 28 Aug 2022 No recent reports of development identified for preclinical development in Cognition-disorders in USA (PO)
  • 28 Aug 2022 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA
  • 28 Aug 2022 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top